Effects of tumor mutation burden on the antigen presentation pathway
Garcia-Rivera, E. M.; Park, J.; Desai, A.; Boidot, R.; Chevrier, S.; Truntzer, C.; Ghiringhelli, F.; Borad, M.; Mansfield, A. S.
Show abstract
Tumor mutation burden (TMB) is used to select patients to receive immune checkpoint inhibitors (ICIs) but has mixed predictive capabilities. We hypothesized that inactivation of antigen presenting genes (APGs) that result from increased TMBs would result in inherent resistance to ICIs. We observed that somatic mutations in APGs were associated with increasing TMBs across 9,418 tumor samples of 33 different histological subtypes. In adenocarcinomas of the lung, ITGAX and CD1B were some of the most commonly mutated APGs. In 62 patients with non-small cell lung cancers treated with a PD-1 inhibitor in second or later lines of therapy, there was an association of increased TMB with mutations in APGs; however, mutations in one or more APGs were associated with improved progression-free survival. Contrary to our hypothesis, mutations in APGs were associated with improved progression-free survival with nivolumab, possibly due to the involvement of single alleles rather than complete loss.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 93%
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events 93%
- A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer 93%
Similar papers in this journal
- Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade 91%
- Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients 90%
- Cumulative COVID-19 incidence, mortality, and prognosis in cancer survivors: a population-based study in Reggio Emilia, Northern Italy 89%
Similar papers in this journal
- Increased Tryptophan, But Not Increased Glucose Metabolism, Predict Resistance of Pembrolizumab in Stage III/IV Melanoma 93%
- MMP2 As An Independent Prognostic Stratifier In Oral Cavity Cancers 92%
- Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients 91%
Similar papers in this journal
- Persistent racial/ethnic associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access 94%
- Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanoma 93%
- ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastrophe 90%
Similar papers in this journal
- TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers 92%
- Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology 90%
- Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.